BPC-157: Structure, Research, and Laboratory Overview

🧬 BPC-157: Comprehensive Research Overview and Structural Analysis

Disclaimer: All information below is for educational purposes only. BPC-157 is supplied strictly as a research compound. It is not intended for human consumption, medical, or veterinary use.

Introduction

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protein found in human gastric juice. With the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, this compound has become a subject of significant scientific interest due to its stability, biological activity in preclinical models, and role in tissue modulation research. Although BPC-157 has not been approved for medical use, numerous in-vitro and in-vivo studies have explored its effects on angiogenesis, cell regeneration, and tissue protection mechanisms.

Molecular Profile

• Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

• Molecular formula: C₆₂H₉₈N₁₆O₂₂

• Molecular weight: 1419.5 g/mol

• Peptide length: 15 amino acids

Its compact structure and hydrophilic properties contribute to its stability in laboratory solutions, making it a reliable candidate for cellular and molecular biology research.

Preclinical Research Highlights

Angiogenesis and Endothelial Response

Research has indicated that BPC-157 may influence angiogenic activity through modulation of VEGFR2, Akt, and eNOS pathways — key mediators in endothelial repair. A pivotal study by Sikiric et al. demonstrated that BPC-157 stimulated endothelial cell tube formation and enhanced angiogenesis in in-vitro and rat ischemia models via activation of the VEGFR2–Akt–eNOS signalling cascade (PubMed 27847966). Additional findings confirmed vascular regeneration in limb ischemia models, supporting its ongoing use in vascular research (J. Physiol. Pharmacol. 2009).

Tissue Healing and Regenerative Studies

Animal research suggests BPC-157 promotes collagen organisation and fibroblast migration, supporting wound closure and structural recovery (PubMed 20388964). In a 2019 Cell and Tissue Research study, both local and systemic administration of BPC-157 improved histological architecture, angiogenesis, and functional recovery in crushed muscle models (Springer Link).

Gastrointestinal and Systemic Protection Models

Because the native compound originates from the gastric system, BPC-157 has been investigated for potential cytoprotective properties in gastrointestinal and organ tissue research. A 2022 review summarised multisystem cytoprotection, noting its influence on the nitric oxide system, oxidative balance, and mucosal protection (MDPI Pharmaceuticals 2022). Additional evidence highlights its protective activity in intestinal, hepatic, and neural injury models (Frontiers in Pharmacology 2021).

Safety and Toxicology

BPC-157 has undergone preclinical toxicological evaluation across multiple species, where it was shown to be well tolerated in tested ranges without significant systemic toxicity (Toxicology Reports, ScienceDirect). These results are limited to controlled laboratory conditions, and no human clinical data exist to support therapeutic application.

Handling and Storage Recommendations

To maintain peptide integrity during laboratory use, store lyophilised BPC-157 at 2–8 °C, away from light and moisture. Once reconstituted, maintain at 2–8 °C for short-term use (up to 14 days) or at –20 °C for long-term storage. Avoid repeated freeze-thaw cycles and use sterile reconstitution solutions such as bacteriostatic water or neutral buffer. These practices align with Good Laboratory Practice (GLP) standards.

Purity and Quality Verification

High-grade BPC-157 should meet or exceed 99% purity, verified by analytical methods such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Each batch should include a Certificate of Analysis (COA), with tamper-evident packaging and full traceability. Adhering to these standards ensures experimental reproducibility and confidence in research outcomes.

Legal Status in the UK

Under UK MHRA and ASA regulations, BPC-157 is classified as a research compound. It is not licensed for human or veterinary use and must not be advertised as having therapeutic effects. It may be purchased and used only in laboratory or scientific research environments with appropriate ethical oversight.

Conclusion

BPC-157 represents a compelling model for ongoing angiogenesis, cell signalling, and tissue repair research. Its well-defined molecular structure and strong preclinical dataset make it a valuable reference compound for researchers investigating peptide-mediated biological pathways. All BPC-157 products available through PeptideShop.co.uk are supplied solely for laboratory research purposes. They are not for human consumption, not medical products, and not for therapeutic use.

References

1. Sikiric P. et al., Therapeutic potential of pro-angiogenic BPC-157 is associated with VEGFR2-Akt-eNOS activation. Biomedicine & Pharmacotherapy (2016). PubMed 27847966

2. Chang C.H. et al., Angiogenesis modulation and VEGF correlation in BPC-157-treated models. J. Physiol. Pharmacol. (2009). Link

3. Vukojevic J. et al., BPC-157 improves muscle regeneration after crush injury. Cell Tissue Res. (2019). Springer

4. Sikiric P. et al., Multifunctionality and Possible Medical Application of the BPC-157. Pharmaceuticals (MDPI, 2022). DOI:10.3390/ph18020185

5. Seiwerth S. et al., Stable Gastric Pentadecapeptide BPC-157 and Wound Healing. Front. Pharmacol. (2021). Frontiers

6. Petrovic P. et al., Toxicology and Safety of BPC-157 in Preclinical Models. Toxicology Reports (2020). ScienceDirect